AstraZeneca Pharma India Performance
- Today's Low
- ₹8,562
- Today's High
- ₹8,662
- 52 Week Low
- ₹7,552
- 52 Week High
- ₹10,691
- Open Price₹8,590
- Previous Close₹8,590
- Volume1,700
- 50 DMA₹8,454.59
- 100 DMA₹8,539.75
- 200 DMA₹8,554.73
AstraZeneca Pharma India Chart
Investment Returns
- Over 1 Month + 1.55%
- Over 3 Month -3.16%
- Over 6 Month -4.46%
- Over 1 Year + 7.89%
Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!
AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 106.9
- PEG Ratio
- 1
- Market Cap Cr
- 21,469
- P/B Ratio
- 25.8
- Average True Range
- 222.56
- EPS
- 83.21
- Dividend Yield
- 0.4
- MACD Signal
- 36.77
- RSI
- 55.39
- MFI
- 74.53
Latest Stock News Updates
AstraZeneca will facilitate the deployment ofQure.ai's AI-powered chest X-ray solution, to be integrated into routine workflows at public health facilities across Telangana
- Business Line
- 1 month 2 weeks ago
AstraZeneca Pharma India Ltd on Tuesday said it has received permission from India's drug regulator to market Durvalumab solution for infusion used in cancer treatment for an additional indication. The company has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, to import for sale and distribution of Durvalumab solution for infusion of strengths 120 mg/2.4 ml and 500 mg/10 ml (brand name Imfinzi) for an additional indication, AstraZeneca Pharma said in a regulatory filing. Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer which is mismatch repair deficient (dMMR). The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 1
- Business Standard
- 3 months 2 weeks ago
Gastric cancer remains a major health challenge in India, ranking as the seventh most common cancer with over 64,000 new cases diagnosed annually
- Business Line
- 3 months 2 weeks ago
AstraZeneca Pharma India Financials
AstraZeneca Pharma India Technicals
EMA & SMA
- Bearish Moving Average 3
- Bullish Moving Average 13
- 20 Day
- ₹8,472.01
- 50 Day
- ₹8,454.59
- 100 Day
- ₹8,539.75
- 200 Day
- ₹8,554.73
Resistance and Support
- R3 8,744.83
- R2 8,703.17
- R1 8,645.33
- S1 8,545.83
- S2 8,504.17
- S3 8,446.33
AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends
About AstraZeneca Pharma India
- NSE Symbol
- ASTRAZEN
- BSE Symbol
- 506820
- Managing Director
- Mr. Praveen Rao Akkinepally
- ISIN
- INE203A01020
Similar Stocks to AstraZeneca Pharma India
Popular Stocks
AstraZeneca Pharma India FAQs
AstraZeneca Pharma India share price is ₹8,587 As on 25 May, 2026 | 02:02
The Market Cap of AstraZeneca Pharma India is ₹21468.8 Cr As on 25 May, 2026 | 02:02
The P/E ratio of AstraZeneca Pharma India is 106.9 As on 25 May, 2026 | 02:02
The PB ratio of AstraZeneca Pharma India is 25.8 As on 25 May, 2026 | 02:02
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.